The discussion highlights Australia's need for a proactive approach in vaccine production and pandemic preparedness. A recent initiative in Victoria to develop mRNA vaccine facilities is seen as a positive long-term investment, especially given the history of emerging coronaviruses. The effectiveness of mRNA technology for rapid vaccine development is emphasized, with suggestions for additional manufacturing facilities to support future vaccine needs. Despite CSL's production of over one million doses of the Oxford vaccine weekly, distribution challenges remain, particularly with vaccination rates. The recent lifting of age restrictions on the AstraZeneca vaccine is noted, along with ongoing efforts to establish mass vaccination hubs. Overall, while Australia has managed to control COVID-19, there is a call for more robust infrastructure to ensure readiness for future health crises.